Syndax Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 41.13 million compared to USD 37.17 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.63 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.75 USD | -1.00% | -1.36% | +0.65% |
May. 08 | Syndax Pharmaceuticals Q1 Net Loss Widens | MT |
May. 08 | Transcript : Syndax Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.65% | 1.85B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- SNDX Stock
- News Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023